Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale
- PMID: 16401156
- DOI: 10.4088/jcp.v66n1209
Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale
Abstract
Objective: Many studies of the treatment of obsessive-compulsive disorder (OCD) have used percent reduction cutoffs on the Yale-Brown Obsessive Compulsive Scale (YBOCS) to classify patients as treatment responders. However, reduction criteria have varied from 20% to 50%, with studies of cognitive-behavioral therapy (CBT) using a more stringent criterion than studies of pharmacotherapy. The aim of this retrospective investigation was to determine optimal YBOCS reduction criteria for classifying patients as responders.
Method: Data from 87 adult clinic and research outpatients meeting DSM-IV-TR criteria for OCD according to structured interview were examined, comparing the percent YBOCS reduction from pretreatment to posttreatment with 2 "gold standard" criteria from the Clinical Global Impressions (CGI) scale: much or very much improved and mild illness or better. Signal detection analyses were used to determine the sensitivity, specificity, predictive value of a positive test, predictive value of a negative test, and efficiency of various YBOCS reduction cutoffs.
Results: A YBOCS reduction cutoff of 30% was optimal for predicting improvement on the CGI. The 20% cutoff used by many pharmacologic studies resulted in a high number of false positives, whereas the 50% cutoff used by most CBT studies resulted in a high number of false negatives. For predicting mild illness or better at posttreatment, a YBOCS reduction cutoff of 40% to 50% was optimal.
Conclusions: A YBOCS reduction criterion of 30% appears to be optimal for determining clinical improvement, whereas a 40% to 50% reduction criterion is appropriate for predicting mild illness at posttreatment. Future studies should employ a standard definition of treatment response in order to facilitate cross-study comparisons.
Similar articles
-
A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder.J Clin Psychiatry. 2006 Jul;67(7):1133-9. doi: 10.4088/jcp.v67n0717. J Clin Psychiatry. 2006. PMID: 16889458 Clinical Trial.
-
Treatment response, symptom remission, and wellness in obsessive-compulsive disorder.J Clin Psychiatry. 2013 Jul;74(7):685-90. doi: 10.4088/JCP.12m07789. J Clin Psychiatry. 2013. PMID: 23945445 Free PMC article. Clinical Trial.
-
The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3. Eur Arch Psychiatry Clin Neurosci. 2010. PMID: 20077119 Clinical Trial.
-
A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.Curr Med Chem. 2018;25(41):5647-5661. doi: 10.2174/0929867325666171222163645. Curr Med Chem. 2018. PMID: 29278206
-
Practice guideline for the treatment of patients with obsessive-compulsive disorder.Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53. Am J Psychiatry. 2007. PMID: 17849776 Review. No abstract available.
Cited by
-
Defining treatment response in pediatric tic disorders: a signal detection analysis of the Yale Global Tic Severity Scale.J Child Adolesc Psychopharmacol. 2011 Dec;21(6):621-7. doi: 10.1089/cap.2010.0149. Epub 2011 Nov 9. J Child Adolesc Psychopharmacol. 2011. PMID: 22070181 Free PMC article.
-
Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder.J Clin Psychiatry. 2018 Jan/Feb;79(1):17l11824. doi: 10.4088/JCP.17l11824. J Clin Psychiatry. 2018. PMID: 29505186 Free PMC article. Clinical Trial. No abstract available.
-
Prediction of Treatment Outcome in Patients with Obsessive-Compulsive Disorder with Low-Resolution Brain Electromagnetic Tomography: A Prospective EEG Study.Front Psychol. 2016 Jan 22;6:1993. doi: 10.3389/fpsyg.2015.01993. eCollection 2015. Front Psychol. 2016. PMID: 26834658 Free PMC article.
-
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.J Clin Psychiatry. 2016 Mar;77(3):408-9. doi: 10.4088/JCP.15l10138. J Clin Psychiatry. 2016. PMID: 27046314 Free PMC article. Clinical Trial. No abstract available.
-
Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder.World Psychiatry. 2016 Feb;15(1):80-1. doi: 10.1002/wps.20299. World Psychiatry. 2016. PMID: 26833615 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical